Rajendra Hippalgaonkar, MD
Cardiovascular Disease · Orange City, FLNPI 1265519052
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $7,698 of the $12,750 with a category attached, or 60.4%. Medtronic accounts for 65.2% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2019 at $8,362 and has fallen 88.5% since, to $963 in 2025.
Across 211 payments — averaging $60.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Merck$619
- Abiomed$522
- Novartis$411
- CMS Imaging, Inc.$346
- E.r. Squibb & Sons, L.L.C.$329
- plus $2K from 28 others
What the payments were for
- Travel & lodging$7,69860%
- Food & beverage$5,01639%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 28 | $8,318 |
| Merck | 33 | $619 |
| Abiomed | 8 | $522 |
| Novartis | 23 | $411 |
| CMS Imaging, Inc. | 1 | $346 |
| E.r. Squibb & Sons, L.L.C. | 27 | $329 |
| Abbott | 7 | $288 |
| Boehringer Ingelheim | 12 | $236 |
| Johnson & Johnson | 10 | $203 |
| Kestra Medical Technology Services, Inc. | 4 | $149 |
| Penumbra, Inc. | 2 | $127 |
| Sanofi-aventis U.S. LLC | 6 | $111 |
| Philips North America LLC | 1 | $111 |
| Amgen | 6 | $97 |
| Cvrx, Inc. | 4 | $97 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $94 |
| Impulse Dynamics (USA) Inc. | 4 | $86 |
| Pfizer | 4 | $76 |
| Boston Scientific | 4 | $64 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $56 |
| Cardiva Medical, Inc. | 2 | $49 |
| AstraZeneca | 3 | $47 |
| Novo Nordisk | 2 | $43 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| Opsens Inc. | 1 | $38 |
| Bard Peripheral Vascular, Inc. | 1 | $33 |
| Cordis US CORP. | 1 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Sanofi | 1 | $18 |
| Teleflex LLC | 1 | $16 |
| Biotronik Inc. | 1 | $13 |
| Livanova USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$7,673
- JOT DX$171
- Impella$128
- Indigo System$125
- Azurion 7 M20$111
- Reveal LINQ$105
How this compares
$12,750 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 992 | $976,008 |
| EntrestoSacubitril/Valsartan | 242 | $251,401 |
| XareltoRivaroxaban | 240 | $218,878 |
| JardianceEmpagliflozin | 69 | $73,651 |
| MultaqDronedarone Hcl | 33 | $54,701 |
| VerquvoVericiguat | 47 | $49,701 |
| BrilintaTicagrelor | 82 | $49,629 |
| Repatha SureclickEvolocumab | 25 | $18,134 |
| FarxigaDapagliflozin Propanediol | 23 | $14,572 |
| Repatha SyringeEvolocumab | 14 | $6,187 |
| Amiodarone Hcl | 204 | $5,694 |
| Metoprolol Succinate | 404 | $5,337 |
| ClopidogrelClopidogrel Bisulfate | 346 | $4,085 |
| Atorvastatin Calcium | 424 | $4,000 |
| Amlodipine Besylate | 536 | $3,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $76 | $976,008992 claims |
| NovartisEntresto | $411 | $251,401242 claims |
| Johnson & JohnsonXarelto | $203 | $218,878240 claims |
| Boehringer IngelheimJardiance | $236 | $73,65169 claims |
| AstraZenecaBrilinta, Farxiga | $47 | $64,201105 claims |
| Sanofi-aventis U.S. LLCMultaq | $111 | $54,70133 claims |
| MerckVerquvo | $619 | $49,70147 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Orange City
- Sameer ChadhaOrange City$132K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.